Diagnosis of Pancreatic Cancer by Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Pancreas Cancer Clinical Trial

Official title:

Development of Pancreatic Cancer Diagnostic Method by Using a Reagent for Analyzing Purine Metabolite (Hypoxanthine, Xanthine) in Urine

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06291779
• Other study ID #: SNUBH-GS- HBP5
• Secondary ID: E-2211-792-350 (
• Status: Recruiting
• Start date: November 30, 2022
• Est. completion date: May 31, 2024

Study information

• Verified date: February 2024
• Source: Seoul National University Hospital
• Contact: MeeYoung Kang, M.D.
• Phone: 82-10-5575-8881
• Email: rime0317[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

• This study aim to develope a diagnostic method of pancreatic cancer by using a reagent for analyzing purine metabolite (Hypoxanthine, Xanthine) in urine.

• It is safe and cost effective compare to radiologic or blood test. It can be used for initial screening test for healty population.

Description:

• CubeBio and Seoul National University Bundang Hospital signed a joint technology development agreement to compare the analytical performance of existing analytical methods and purine metabolite analysis reagents developed by CubeBio.

• Through quantitative analysis of hypoxanthine and xanthine in the urine of normal people and pancreatic cancer patients, we plan to confirm the possibility of diagnosing pancreatic cancer using reagents for analyzing purine metabolites.

• Early diagnosis of pancreatic cancer is a key determinant of cure and survival rates, and impact on all aspects of cancer, including rate of progression, treatment, and prognosis.

• This study could change the paradigm of pancreatic cancer screening by evaluating the stability and accuracy of urinary purine metabolite analysis reagents.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: May 31, 2024
• Est. primary completion date: February 26, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

1. pancreatic cancer group

Inclusion Criteria:

• Pancreatic ductal adenocarcinoma that is pathologically confirmed or shows characteristic radiologic features

• Patients with resectable pancreatic cancer at the time of surgery (Including borderline resectable pancreatic cancer at the time of diagnosis or Locally advanced pancreatic cancer after chemotherapy or radiation therapy)

• Patients without invasion of adjacent organs other than the left adrenal gland and mesocolon

• Patients with informed consent

Exclusion Criteria:

• History of other malignancy (Inclusive if there is no evidence of recurrence after 5 years of treatment)

• Patient with Inflammatory disease(e.g. severe pancreatitis, cholangitis)

• Patients with underlying diseases at high risk of general anesthesia

• Other subject whom the investigator deems inappropriate

2. control group Inclusion Criteria included healthy individuals as well as patients with benign diseases.

Exclusion criteria for the control group included a previous cancer diagnosis within the past five years, active inflammatory diseases, borderline malignant pancreatic tumors, or a postoperative pathological finding of malignancy.

Related Conditions & MeSH terms

• Diagnosis
• Disease
• Pancreas Cancer
• Pancreatic Neoplasms

Intervention

Device:
• Purine metabolite (Hypoxanthine, Xanthine) in urine by CubeBio
Collect urine from the patient to measure urinary hypoxia, xanthine concentration. Hypoxic acid, xanthine analysis in urine using High Performance Liquid Chromatography (HPLC). After that, hypoxanthine and xanthine will be analyzed using purine metabolite analysis reagents. Compare the cutoff of the metabolic value of Pancreas cancer clarified in the existing research and the value of the sample.

Locations

Country	Name	City	State
Korea, Republic of	Ho-Seong Han	Seongnam	Gyeonggi-do

Sponsors (2)

Lead Sponsor	Collaborator
Ho-Seong Han	Seoul National University Bundang Hospital

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (1)

Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 2009 Aug 19;648(1):98-104. doi: 10.1016/j.aca.2009.06.033. Epub 2009 Jun 21. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Urine	mean concentration of purine metabolites in urine	1 day